Hollywood's most eclectic awards show will recognize the year's best in film, television and even podcasts on Jan. 11.

BERLIN () -German pharma company Bayer reported positive study ​results for its anticoagulant asundexian on Sunday,‌ two years after a research setback for the ‌promising blood thinner candidate. In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared ⁠with a placebo,‌ Bayer said.

"I couldn't imagine life without him anymore," Melanie Smith said.